424 related articles for article (PubMed ID: 29953622)
21. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
22. Expression of c-erbB receptors and ligands in the bronchial epithelium of asthmatic subjects.
Polosa R; Puddicombe SM; Krishna MT; Tuck AB; Howarth PH; Holgate ST; Davies DE
J Allergy Clin Immunol; 2002 Jan; 109(1):75-81. PubMed ID: 11799369
[TBL] [Abstract][Full Text] [Related]
23. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
[TBL] [Abstract][Full Text] [Related]
24. Growth factor receptors and their ligands.
Eppenberger U; Mueller H
J Neurooncol; 1994; 22(3):249-54. PubMed ID: 7760103
[TBL] [Abstract][Full Text] [Related]
25. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
26. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
27. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
28. Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation.
Faria JAQA; de Andrade C; Goes AM; Rodrigues MA; Gomes DA
Biochem Biophys Res Commun; 2016 Sep; 478(1):39-45. PubMed ID: 27462018
[TBL] [Abstract][Full Text] [Related]
29. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture.
Huotari MA; Miettinen PJ; Palgi J; Koivisto T; Ustinov J; Harari D; Yarden Y; Otonkoski T
Endocrinology; 2002 Nov; 143(11):4437-46. PubMed ID: 12399441
[TBL] [Abstract][Full Text] [Related]
30. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
31. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
[TBL] [Abstract][Full Text] [Related]
32. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.
Guo G; Gong K; Ali S; Ali N; Shallwani S; Hatanpaa KJ; Pan E; Mickey B; Burma S; Wang DH; Kesari S; Sarkaria JN; Zhao D; Habib AA
Nat Neurosci; 2017 Aug; 20(8):1074-1084. PubMed ID: 28604685
[TBL] [Abstract][Full Text] [Related]
33. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
34. DSE promotes aggressive glioma cell phenotypes by enhancing HB-EGF/ErbB signaling.
Liao WC; Liao CK; Tsai YH; Tseng TJ; Chuang LC; Lan CT; Chang HM; Liu CH
PLoS One; 2018; 13(6):e0198364. PubMed ID: 29864158
[TBL] [Abstract][Full Text] [Related]
35. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.
Moriai T; Kobrin MS; Hope C; Speck L; Korc M
Proc Natl Acad Sci U S A; 1994 Oct; 91(21):10217-21. PubMed ID: 7937865
[TBL] [Abstract][Full Text] [Related]
36. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
37. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
38. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
[TBL] [Abstract][Full Text] [Related]
39. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
